DTX3L通过FAK/PI3K/AKT轴加速胰腺癌的进展
Liang Chen1,2,3, Wenyang Niu2, Hong Zang4
1Department of Hepatobiliary Pancreatic Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.
Biochemical genetics
|July 17, 2023
概括
德尔泰克斯E3泛素酶3L (DTX3L) 通过稳定表皮生长因子受体 (EGFR) 来促进胰腺癌的进展. DTX3L上调加速瘤生长并降低化疗敏感性,这表明它是潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 德尔泰克斯E3泛素酶3L (DTX3L),也称为B淋巴瘤和BAL相关蛋白 (BBAP),是一种E3泛素酶,涉及瘤发育.
- DTX3L在胰腺癌病原发生中的特定作用以前没有被阐明.
研究的目的:
- 研究DTX3L在胰腺癌中的表达和功能.
- 阐明DTX3L影响胰腺癌进展的潜在分子机制.
主要方法:
- 在胰腺癌组织中分析DTX3L表达的分析,使用TCGA数据库,qRT-PCR和Western blot.
- 功能分析包括CCK8,殖民地形成,Transwell和伤口愈合分析,以评估细胞增殖,入侵和迁移.
- 使用相关实验模型研究分子相互作用和通路激活 (EGFR,FAK/PI3K/Akt).
- 评估DTX3L对 орто植入体瘤模型中化疗敏感性的影响.
主要成果:
- DTX3L在胰腺癌组织中显著上调,与患者的存活率有负相关性.
- 过度表达DTX3L增强了胰腺癌细胞的增殖,入侵和迁移.
- DTX3L通过抑制其无处不在和降解来稳定表皮生长因子受体 (EGFR).
- 激活的EGFR触发了FAK/PI3K/Akt通路,促进了胰腺癌的进展.
- DTX3L可以降低胰腺癌细胞对化疗的敏感性.
结论:
- DTX3L通过EGFR依赖的FAK/PI3K/Akt通路的激活来加速胰腺癌的进展.
- DTX3L代表了胰腺癌治疗的潜在治疗标.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
01:35Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K